Pooling failed trials with successful ones, then declaring amyloid a dead end, isn’t caution — it’s overreach. In his latest Policy Dispatch, Lenny Shallcross argues the field is asking the right question: how much further can this go? Learn more: bit.ly/3R3rBnm
